CN Patent

CN113773304B — 抗耐药抗肿瘤egfr抑制剂的制备方法

Assigned to Jiangsu Hansoh Pharmaceutical Group Co Ltd · Expires 2023-03-10 · 3y expired

What this patent protects

本发明涉及一种抗耐药抗肿瘤EGFR抑制剂的制备方法。具体地，本发明涉及一种通式(IV)所示化合物结构的4‑(1‑环丙基‑1H‑吲哚‑3‑基)‑N‑苯基嘧啶‑2‑胺衍生物的制备方法。本发明方法克服了现有技术中存在的缺陷，大大缩减了成本，所得产物纯度好、收率高、工艺可操作性强，工艺安全性也得到大幅提高。因此，本发明制备方法及其应用适合工业化应用。

USPTO Abstract

本发明涉及一种抗耐药抗肿瘤EGFR抑制剂的制备方法。具体地，本发明涉及一种通式(IV)所示化合物结构的4‑(1‑环丙基‑1H‑吲哚‑3‑基)‑N‑苯基嘧啶‑2‑胺衍生物的制备方法。本发明方法克服了现有技术中存在的缺陷，大大缩减了成本，所得产物纯度好、收率高、工艺可操作性强，工艺安全性也得到大幅提高。因此，本发明制备方法及其应用适合工业化应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN113773304B
Jurisdiction
CN
Classification
—
Expires
2023-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.